Abstract
The parasympatholytic drugs, the antihistamines, and the phenothiazine tranquilizers all have a central depressant action and have long been used in preventing or treating motion sickness. The most widely used drugs are those with few atropine-like or sedative side-effects and thanks to the interest of the armed forces, many field studies and clinical trials evaluating drugs against motion sickness are available [1, 2]. In 1966, Brand and Perry [3] compiled exhaustive reviews on drugs used in motion sickness. They reported that there is no substitute for l-hyoscine (scopolamine) where the aim is to provide quick action but short-term protection against exposure to severe motion, but that for the prophylaxis of motion sickness during a long voyage, the diphenhydramine, cyclizine, may afford adequate protection.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Graybiel A, Cramer DB, Wood CD (1982) Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration. Aviat Space Environ Med 53: 770–772
Pyykko I, Padoan S, Schalen L, Lyttkens L, Magnusson M, Henriksson NG (1985) The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus. Aviat Space Environ Med 56: 777–782
Brand JJ, Perry WLM (1966) Drugs used in motion sickness. Pharmacol Rev 18: 895–924
Shaw JE, Bayne W, Schmitt LG (1976) Clinical pharmacology of scopolamine. Clin Pharmacol Ther 19: 15–19
Wood CD, Graybiel A (1970) Evaluation of antimotion sickness drugs. A new effective remedy revealed. Aerospace Med 41: 932–933
Shute CC, Lewis PR (1963) Cholinesterase-containing systems of the brain of the rat. Nature 199: 1160–1164
Shute CC, Lewis PR (1965) Cholinesterase-containing pathways of the hindbrain. Afferent cerebellar and centrifugal cochlear fibers. Nature 205: 242–246
Parrott AC (1989) Transdermal scopolamine. A review of its effects upon motion sickness, psychological performance, and physiological functioning. Aviat Space Environ Med 60: 1–9
Balon RW (1983) The dizzy patient. Symptomatic treatment of vertigo. Postgrad Med 73: 317–324
Babin RW, Balkany TJ, Fee WE (1984) Transdermal scopolamine in the treatment of acute vertigo. Ann Otol Rhinol Laryngol 93: 25–27
Rahko T, Karma P (1985) Transdermal scopolamine for peripheral vertigo (a double-blind study). J Laryngol Otol 99: 653–656
Lenore G, Schmitt RN, Shaw JE (1986) Alleviation of induced vertigo. Arch Otolaryngol Head Neck Surg 112: 88–91
Pyykkò I, Magnusson M, Schalen K, Enbom H (1988) Pharmacological treatment of vertigo. Acta Otolaryngol [Suppl] (Stockh) 455: 77–81
Jaju BP, Kirsten EB, Wang SC (1970) Effects of belladonna alkaloids on vestibular nucleus of the cat. Am J Physiol 219: 1248–1255
Kohl RL, Homick JL (1983) Motion sickness, a modulatory role for the central cholinergic nervous system. Neurosci Biobehav Rev 7: 73–85
Klein BL, Ashenburg CA, Reed MD (1985) Transdermal scopolamine intoxication in a child. Pediatr Emerg Care 1: 208–209
Wilkinson JA (1987) Side effects of transdermal scopolamine. J Emerg Med 5: 389–392
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Tokyo
About this chapter
Cite this chapter
Kumoi, T., Inamori, T., Mori, H. (1990). Transdermal Scopolamine in the Treatment of Vertiginous Episodes Associated with Ménière’s Disease. In: Kitahara, M. (eds) Ménière’s Disease. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68111-3_23
Download citation
DOI: https://doi.org/10.1007/978-4-431-68111-3_23
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-68113-7
Online ISBN: 978-4-431-68111-3
eBook Packages: Springer Book Archive